Personalized Exercise Training to Improve Functional Capacity in Transthyretin Cardiac Amyloidosis

What this Trial Is About

Transthyretin cardiac amyloidosis (ATTR-CM) causes serious heart failure primarily in older adults, affecting around 10% of those over 65 with heart failure. This condition leads to significant illness and death, with muscle problems starting years before heart failure symptoms. Researchers are studying a personalized exercise program to improve physical ability and quality of life for patients already receiving optimal treatment with tafamidis, the only approved medication that slows disease progression but does not improve exercise capacity. The study involves a supervised, personalized exercise training program with two 60-minute sessions per week for 12 weeks. The program aims to improve skeletal muscle function and aerobic capacity in people with ATTR-CM. Tests like cardiopulmonary exercise testing and muscle strength assessments will compare muscle performance between ATTR-CM patients and others with heart failure, and measure benefits from the exercise. Participants will be assessed with exercise tests, quality of life questionnaires, and physical function tests over the 12-week intervention. Researchers will monitor peak oxygen consumption and lower extremity function to evaluate improvements. The study requires participants to be clinically stable, able to walk and perform daily activities independently. The research will last until June 2030, with careful monitoring of safety and adherence throughout.

Exercise Training in Transthyretin Cardiac Amyloidosis